Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph Ciccolini

Showing results (91-100 of 168) with videos related to

Pageof 17
Sort By:
Current Topics in Medicinal Chemistry|September 18, 2012
Population pharmacokinetic analysis of 5-FU and 5-FDHU in colorectal cancer patients: search for biomarkers associated with gastro-intestinal toxicityChristian Woloch, Antonello Di Paolo, Hafedh Marouani, et al.
Molecular Cancer Therapeutics|December 24, 2005
Response of endothelial cells to a dual tyrosine kinase receptor inhibition combined with irradiationAlexandre Bozec, Patricia Formento, Joseph Ciccolini, et al.
Anti-Cancer Drugs|February 16, 2005
Taxotere-5'-deoxy-5-fluorouridine combination on hormone-refractory human prostate cancer cellsJean-Louis Fischel, Jean-Marc Ferrero, Patricia Formento, et al.
Pharmaceutical Research|February 7, 2013
In vitro and in vivo evaluation of lipofufol, a new triple stealth liposomal formulation of modulated 5-fu: impact on efficacy and toxicityRaphaelle Fanciullino, Séverine Mollard, Sarah Giacometti, et al.
Cancer Research|June 29, 2017
Pharmacokinetics and Pharmacodynamics-Based Mathematical Modeling Identifies an Optimal Protocol for Metronomic ChemotherapyJoseph Ciccolini, Dominique Barbolosi, Christophe Meille, et al.
International Journal of Pharmaceutics|April 8, 2024
Pegylated liposome encapsulating docetaxel using microfluidic mixing technique: Process optimization and results in breast cancer modelsMathilde Dacos, Benoît Immordino, Erwan Diroff, et al.
Clinical Cancer Drugs|April 24, 2018
UPFRONT DPD DEFICIENCY DETECTION TO SECURE 5-FU ADMINISTRATION: PART 2- APPLICATION TO HEAD-AND-NECK CANCER PATIENTSManon Launay, Joseph Ciccolini, Claire Fournel, et al.
Cancer Research|June 16, 2016
Mathematical Modeling of Cancer Immunotherapy and Its Synergy with RadiotherapyRaphael Serre, Sebastien Benzekry, Laetitia Padovani, et al.
Pharmacogenetics and Genomics|April 9, 2015
Lethal toxicity after administration of azacytidine: implication of the cytidine deaminase-deficiency syndromeRaphaelle Fanciullino, Cedric Mercier, Cindy Serdjebi, et al.
British Journal of Haematology|September 11, 2023
Cytidine deaminase status as a marker of response to azacytidine treatment in MDS and AML patientsMelanie Donnette, Mourad Hamimed, Joseph Ciccolini, et al.
Pageof 17

Showing results (91-100 of 168) with videos related to

Sort By:
Pageof 17
Current Topics in Medicinal Chemistry|September 18, 2012
Population pharmacokinetic analysis of 5-FU and 5-FDHU in colorectal cancer patients: search for biomarkers associated with gastro-intestinal toxicityChristian Woloch, Antonello Di Paolo, Hafedh Marouani, et al.
Molecular Cancer Therapeutics|December 24, 2005
Response of endothelial cells to a dual tyrosine kinase receptor inhibition combined with irradiationAlexandre Bozec, Patricia Formento, Joseph Ciccolini, et al.
Anti-Cancer Drugs|February 16, 2005
Taxotere-5'-deoxy-5-fluorouridine combination on hormone-refractory human prostate cancer cellsJean-Louis Fischel, Jean-Marc Ferrero, Patricia Formento, et al.
Pharmaceutical Research|February 7, 2013
In vitro and in vivo evaluation of lipofufol, a new triple stealth liposomal formulation of modulated 5-fu: impact on efficacy and toxicityRaphaelle Fanciullino, Séverine Mollard, Sarah Giacometti, et al.
Cancer Research|June 29, 2017
Pharmacokinetics and Pharmacodynamics-Based Mathematical Modeling Identifies an Optimal Protocol for Metronomic ChemotherapyJoseph Ciccolini, Dominique Barbolosi, Christophe Meille, et al.
International Journal of Pharmaceutics|April 8, 2024
Pegylated liposome encapsulating docetaxel using microfluidic mixing technique: Process optimization and results in breast cancer modelsMathilde Dacos, Benoît Immordino, Erwan Diroff, et al.
Clinical Cancer Drugs|April 24, 2018
UPFRONT DPD DEFICIENCY DETECTION TO SECURE 5-FU ADMINISTRATION: PART 2- APPLICATION TO HEAD-AND-NECK CANCER PATIENTSManon Launay, Joseph Ciccolini, Claire Fournel, et al.
Cancer Research|June 16, 2016
Mathematical Modeling of Cancer Immunotherapy and Its Synergy with RadiotherapyRaphael Serre, Sebastien Benzekry, Laetitia Padovani, et al.
Pharmacogenetics and Genomics|April 9, 2015
Lethal toxicity after administration of azacytidine: implication of the cytidine deaminase-deficiency syndromeRaphaelle Fanciullino, Cedric Mercier, Cindy Serdjebi, et al.
British Journal of Haematology|September 11, 2023
Cytidine deaminase status as a marker of response to azacytidine treatment in MDS and AML patientsMelanie Donnette, Mourad Hamimed, Joseph Ciccolini, et al.
Pageof 17